Nasdaq Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise

Realtime	Geld	Brief	Zeit
	237,40	240,10	17.09.
	237,60	239,50	17.09.

Realtime

Geld

Brief

Zeit

237,40

240,10

17.09.

237,60

239,50

17.09.

Nasdaq Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise

The share capital of Genmab A/S has been increased. The admittance to trading
and official listing will take effect as per 13 September 2024 in the ISIN
below. 



ISIN:         DK0010272202             
------------------------------------------------------------
Name:         Genmab                
------------------------------------------------------------
Volume before change: 66,165,102 shares (DKK 66,165,102)  
------------------------------------------------------------
Change:        11,729 shares (DKK 11,729)      
------------------------------------------------------------
Volume after change:  66,176,831 shares (DKK 66,176,831)  
------------------------------------------------------------
Subscription prices:  ·     4,623 shares - DKK 1,025.00
            ·     3,656 shares - DKK 1,032.00
            ·     561 shares - DKK 1,050.00 
            ·     1,645 shares - DKK 1,334.50
            ·     1,015 shares - DKK 1,432.00
            ·     229 shares - DKK 1,615.00 
------------------------------------------------------------
Face value:      DKK 1                
------------------------------------------------------------
Short name:      GMAB                 
------------------------------------------------------------
Orderbook ID:     11143                
------------------------------------------------------------



For further inform-ion, please contact: Surveillance, tel. +45 33 93 33 66

Sondersituation: Vervielfachungschance bei diesen Goldaktien

Der Goldpreis haussiert und schwingt sich von Hoch zu Hoch. Getrieben von geopolitischen Unsicherheiten sowie der Aussicht auf eine lockere Geldpolitik der FED gehen Experten aktuell von weiter steigenden Notierungen bis sogar in den Bereich von 3.000 US-Dollar je Unze Gold aus.

Im Schatten des Basispreises notieren Goldproduzenten aus der zweiten Reihe sowie Explorationsunternehmen noch weit weg von ihren historischen Höchstständen entfernt und bieten dadurch erhebliches Aufholpotential.

In diesem kostenlosen Report geben wir Ihnen Favoriten an die Hand, die aufgrund von Sondersituation die Chance auf eine Kursvervielfachung besitzen.

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von dem weiter steigenden Kurs des Edelmetalls.

Sichern Sie sich jetzt Ihren kostenfreien Report.

Hier klicken

Zeit	Aktuelle Nachrichten
So	Genmab A/S: Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial	Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed... ► Artikel lesen
Fr	H.C. Wainwright maintains Genmab shares at Buy on trial results
11.09.	Nasdaq Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise	The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect as per 13 September 2024 in the ISIN below. ISIN: DK0010272202 ... ► Artikel lesen
10.09.	Genmab reports capital increase from employee warrants
10.09.	GENMAB A/S - 6-K, Report of foreign issuer

Zeit

Aktuelle Nachrichten

Genmab A/S: Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed...
► Artikel lesen

H.C. Wainwright maintains Genmab shares at Buy on trial results

11.09.

Nasdaq Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise

The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect as per 13 September 2024 in the ISIN below. ISIN: DK0010272202 ...
► Artikel lesen

10.09.

Genmab reports capital increase from employee warrants

10.09.

GENMAB A/S - 6-K, Report of foreign issuer

	Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Xetra-Orderbuch


	Fonds	Kurs	%


	Devisen	Kurs	%


	Rohstoffe	Kurs	%


	Themen	Kurs	%



Erweiterte Suche